Androstanolone enanthate

Androstanolone enanthate
Clinical data
Trade names	Anaboleen Depot
Other names	Stanolone enanthate; Dihydrotestosterone enanthate; DHT enanthate; Dihydrotestosterone heptanoate; DHTH; 5α-Androstan-17β-ol-3-one 17β-heptanoate
Routes of; administration	Intramuscular injection
Drug class	Androgen; Anabolic steroid; Androgen ester
Identifiers
	IUPAC name [(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] heptanoate;
CAS Number	33776-88-4;
PubChem CID	160230;
ChemSpider	140831;
UNII	UAQ3N36A25;
CompTox Dashboard (EPA)	DTXSID90955358 ;
Chemical and physical data
Formula	C26H42O3
Molar mass	402.619 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)C4)C)C;
	InChI InChI=1S/C26H42O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h18,20-23H,4-17H2,1-3H3/t18-,20-,21-,22-,23-,25-,26-/m0/s1; Key:DDYHAKNCTGGYOK-LVYWIKMTSA-N;

Androstanolone enanthate (brand name Anaboleen Depot), also known as stanolone enanthate or dihydrotestosterone heptanoate (DHTH), as well as 5α-androstan-17β-ol-3-one 17β-heptanoate, is a synthetic androgen and anabolic steroid and a dihydrotestosterone ester.^[1]^[2] It is used as an injectable and acts as a prodrug of androstanolone (stanolone, dihydrotestosterone, DHT). The drug has been studied in and found to be effective in the treatment of gynecomastia in boys and adult men.^[3]^[4]^[5] The pharmacology of androstanolone enanthate has been studied.^[6]^[7]

References

^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.
^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
^ Swerdloff RS, Wang C (October 1998). "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Bailliere's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. PMID 10332569.
^ Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–149. doi:10.1016/s0022-3476(86)80596-0. PMID 3088241.
^ Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMC 6459338. PMID 28472278.
^ Keenan BS, Eberle AJ, Sparrow JT, Greger NG, Panko WB (March 1987). "Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function". The Journal of Clinical Endocrinology and Metabolism. 64 (3): 557–562. doi:10.1210/jcem-64-3-557. PMID 3546348.
^ Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–2098. doi:10.1093/clinchem/43.11.2091. PMID 9365393.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This article about an Androgen is a stub. You can help Wikipedia by expanding it.

[Elks2014-1] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN 978-1-4757-2085-3.

[MortonHall2012-2] Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.

[SwerdloffWang1998-3] Swerdloff RS, Wang C (October 1998). "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Bailliere's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. PMID 10332569.

[pmid3088241-4] Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–149. doi:10.1016/s0022-3476(86)80596-0. PMID 3088241.

[SwerdloffDudley2017-5] Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMC 6459338. PMID 28472278.

[KeenanEberle1987-6] Keenan BS, Eberle AJ, Sparrow JT, Greger NG, Panko WB (March 1987). "Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function". The Journal of Clinical Endocrinology and Metabolism. 64 (3): 557–562. doi:10.1210/jcem-64-3-557. PMID 3546348.

[pmid9365393-7] Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–2098. doi:10.1093/clinchem/43.11.2091. PMID 9365393.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Androstanolone enanthate

Hub talks

Androstanolone enanthate

Androstanolone enanthate

Hub rules

Androstanolone enanthate

Hub overview

Add your contribution

Inside this hub

Media Collections

Timelines

Articles

Notes collections

Notes

Days in Chronicle

Root Wikipedia Article

Androstanolone enanthate

See also

References

Add your contribution

Related Hubs